Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Seoul National University R & Db Foundation has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and the distinct art units. This distribution suggests a diversified prosecution strategy where every active matter is being reviewed by a different official in a different administrative unit. Barber, Kimberly is identified as the busiest examiner with 1 pending office action.
Since the distinct examiners each hold a pending action, the workload is balanced across the portfolio. This requires the foundation to manage separate examination tracks simultaneously, each subject to the unique requirements of its respective art unit. The involvement of the 4 distinct art units indicates that the university's biotechnology research spans multiple specialized classifications. With the distinct examiners involved, the foundation must adapt to different sets of examiner expectations to advance the pending office actions. The 1 pending office action under Barber, Kimberly is a component of this portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARBER, KIMBERLY | 1 | 73.6% | +18.5% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277637 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704561 | GENE DELIVERY COMPOSITION COMPRISING NITROGEN-DOPED GRAPHENE QUANTUM DOTS | BARBER, KIMBERLY | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704561 | GENE DELIVERY COMPOSITION COMPRISING NITROGEN-DOPED GRAPHENE QUANTUM DOTS | BARBER, KIMBERLY | 17d overdue |
| 18042806 | MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR | YOUNG, MICAH PAUL | 15d |
| 17258105 | GRAPHENE QUANTUM DOT AS THERAPEUTIC AGENT FOR DISEASE ASSOCIATED WITH ABNORMAL FIBRILLATION OR AGGREGATION OF NEUROPROTEIN | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1621 | 1 |
| 1618 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704561 | GENE DELIVERY COMPOSITION COMPRISING NITROGEN-DOPED GRAPHENE QUANTUM DOTS | BARBER, KIMBERLY | 1615 | §103§112 | Final Rejection | 17d overdue | Pending | Apr 25, 2024 |
| 18277637 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | AULAKH, CHARANJIT | 1621 | §103 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18042806 | MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | 15d | Pending | Feb 24, 2023 |
| 17258105 | GRAPHENE QUANTUM DOT AS THERAPEUTIC AGENT FOR DISEASE ASSOCIATED WITH ABNORMAL FIBRILLATION OR AGGREGATION OF NEUROPROTEIN | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | — | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial